Aspira Women's Health receives Nasdaq delisting notice for MVLS non-compliance

Aspira Women's Health Inc.

Notice received Dec 31, 2024; company failed to regain $35M MVLS requirement by Dec 30, 2024 deadline.
Unless appeal requested by Jan 7, 2025 with $20,000 fee, common stock delisted Jan 10, 2025.
Company intends to appeal; appeal stays delisting pending Nasdaq decision.
No assurance of success; risk of delisting from Nasdaq Capital Market remains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.